FiercePharmaAsia: FibroGen and AZ’s anemia filing in China, Astellas’ eardrum therapy buy, Takeda’s price control promise

FibroGen and AstraZeneca prepares for an NDA filing in China for their promising anemia drug.

Welcome to this week’s FiercePharmaAsia report, which includes an upcoming new drug application by FibroGen and AstraZeneca in China, a ruptured eardrum med's rights transfer to Astellas, and Takeda's single-digit price-hike promise.

1. Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing

FibroGen has posted positive phase 3 data on its anemia drug roxadustat carried out in China and is on the move for an approval in the country. With a “green channel” fast regulatory process, FibroGen plans to complete the NDA later this year. Once approved, FibroGen will handle manufacturing, and its partner AstraZeneca will focus on the launch and commercialization.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

2. Astellas buys rights to Auration's ruptured eardrum therapy

Astellas has obtained worldwide rights to AU-935 from Auration Biotech. The drug, first discovered at Stanford University, could be used to make eardrums regenerate, therefore providing an alternative to surgery for tympanic membrane perforation, commonly known as a ruptured eardrum. Another Japanese drugmaker Nobelpharma is also in the latter stages of developing a formulation for the disease.

3. Takeda joins pharma peers in single-digit price-hike promise

Takeda just joined three other pharma companies—Allergan, Novo Nordisk and AbbVie—that promise to keep yearly drug price increment below 10%. Merck, though making no specific promises to set a number, recently released a Pricing Action Transparency Report showing their increases have been modest.

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.